Staidson announced that the summary report of Phase I clinical study of STSA-1301 subcutaneous injection for the treatment of primary immune thrombocytopenia was obtained. The results showed that the safety and tolerability of STSA-1301 subcutaneous injection in healthy subjects after a single dose were good, exhibiting non-linear pharmacokinetic characteristics. It can dose-dependently reduce the serum total IgG level, with the maximum decrease occurring between 5-14 days after administration. There was some immunogenicity in the high-dose group but there were no observed effects on PK, PD, and safety. No effects were observed on IgA, IgM, IgD, IgE, and cytokines.
舒泰神：取得STSA-1301皮下注射液用于治疗原发性免疫性血小板减少症的Ia期临床研究总结报告
Staidson: Summary report of the phase Ia clinical study of STSA-1301 subcutaneous injection for the treatment of primary immune thrombocytopenia.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.